Antonio Henriques

Epic

Amid all the warnings about a ‘dementia tsunami’, here are the things you should know | Devi Sridhar When we dig into new research we see why all the alarming headlines are written, but also that science is bringing new hope, says Devi Sridhar, chair of global public health at the University of Edinb...

"Amid all the warnings about a ‘dementia tsunami’, here are the things you should know.

When we dig into new research we see why all the alarming headlines are written, but also that science is bringing new hope."

🧪🧠 #neuroskyence

www.theguardian.com/commentisfre...

God, it's brutal out here

No better way to kick off this next chapter than spending my first full day in Boston—after 8 years in California—at the MassBio conference. Grateful for the warm welcome and excited for what’s ahead.

Interleukin-12 signaling drives Alzheimer’s disease pathology through disrupting neuronal and oligodendrocyte homeostasis - Nature Aging Schneeberger, Kim, Geesdorf, Rajewsky, Heppner et al. tease IL-12 and IL-23 signaling apart in mouse models and human brain tissue to define a role for oligodendroglial and neuronal IL-12 signaling in...

Interleukin-12 signaling drives Alzheimer’s disease pathology through disrupting neuronal and oligodendrocyte homeostasis www.nature.com/articles/s43...

Regardless of how unfair it is that these projects receive funding while therapeutics do not, these mice are ridiculously cute

Watching Severance and interpreting it as a TV show about an intricate clinical trial design makes it even more mind-blowing

Governments should aim to become leaner—when it’s feasible to do more with less. But shedding weight at record speed by cutting off both arms and legs isn’t exactly a winning long-term strategy

Feels like Christmas morning—can’t wait to read this one!
@charlespiller.bsky.social

Why limit yourself to developing neurodegenerative therapies when you can also create art?

With a cofounder who’s both a scientist and an artist, the possibilities are endless 👨🏻‍🔬👨🏻‍🎨

Excited to share that I'll be attending the Global Healthspan Summit 2025 as Momentum Therapeutics continues advancing our mission to develop novel therapies that protect the nervous system and combat aging.

If you'll be there, let’s connect!

#Hevolution #Healthspan #GHS2025

Propagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease - Nature Neuroscience Yuan et al. find that the kidney can serve as a site of initiation for the spread of pathological α-synuclein to the brain, contributing to the development of Parkinson’s disease (PD) and providing a ...

We knew about the potential origin of Parkinson's disease from the gut (known as Braak’s hypothesis). But the kidney?!
www.nature.com/articles/s41...

This is the mantra.

Insitro’s CEO Daphne Koller for Endpoints:

A neurologist with 2 APOE4 copies tells us about his experience with #Alzheimers disease
washingtonpost.com/wellness/202...

Argentina is the only country in South America with Nobel Prizes in scientific categories, and has made significant contributions to global science, particularly in biochemistry and medicine.

Neuroinflammation in Alzheimer disease - Nature Reviews Immunology This Review provides an in-depth examination of how inflammation contributes to neurodegeneration in Alzheimer disease. The authors explore the impact of extrinsic factors, such as brain trauma, diet ...

it's big, and it's a review of 601 papers on the topic - but here's an update on Neuroinflammation in Alzheimer's Disease
www.nature.com/articles/s41...

led by Michael Heneka, published in @natrevimmunol.bsky.social today

(MANY more authors listed and linked below)

Brain delivery has the potential to transform patient care - and it could become a reality soon. This snapshot of transcytosis strategies (from GS) highlights how neurobiotech is on the verge of revolutionizing treatments for CNS diseases. I only wish Montara had been included in the discussion.

A sincere and shameless plug: This Thanksgiving, I’m especially grateful for my healthy axons.

Photo Credit: Felipe Court, our Chief Scientific Officer.

My advice to graduates of my class who still (!) insist on going into #biotech investment banking

First, a few tips re science/medical data:

I would actually be curious to understand what sets the biotechs with 24+ months of cash apart in this environment. AI-focused companies? Products of large VC firm incubators? Another common thread driving their extended runway?

Would love to join!

Neuroscience and obesity continue to stand out as the dominant and perhaps only major headwinds driving biopharma business development this year, consistently delivering impressive deals and partnerships.

Made a biotech founders starter pack, DM me to be added!

go.bsky.app/LWm8uPE

Awesome, thank you!

Nice, thanks!

Who’s building a neuroscience and a biotech founder “starter packs”? #biosky #medsky

Proud to be part of this movement alongside brilliant peers and friends shaping the future of innovation in biotech.

First post here! Excited to connect, learn, and join meaningful conversations. #BioSky #SciSky